SEC Form 4 · accession 0001140361-26-024784
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ying Luo
Officer — Chief Executive Officer · Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 10, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.05 | Jun 8, 2026 | A | 120,000 | A | — | Jun 8, 2036 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.